NewsRx

Search our medical news database

Apoptosis

Studies from National Institutes of Health have provided new data on apoptosis

Published in Vaccine Weekly, July 2nd, 2008

"CD4(+) helper T cells contribute to the induction and maintenance of antigen-specific CD8(+) T cells. Their absence results in short-lived antigen-specific CD8(+) T cells and defective secondary CD8(+) T cell responses because of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis," scientists in the United States report.

"Here, we show that IL-15 codelivered with vaccines can overcome CD4(+) T cell deficiency for promoting longevity of antigen-specific CD8(+) T cells and avoidance of TRAIL-mediated apoptosis. In both priming and secondary responses, IL-15 down-regulates proapoptotic Bax, an intermediate in TRAIL-mediated apoptosis, and...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook